FR0010331421
© BusinessWire
28.11.2025
IPH
LISTED
EURONEXT
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
News Preview
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well...
Themefolio
Profiler
Peergroup
© BusinessWire
17.11.2025
IPH
LISTED
EURONEXT
Innate Pharma to Present at Jefferies Global Healthcare Conference
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of its executive team will participate in one-on-one meetings and present on Monday, November 17, 2025.
Jefferies Global Healthcare Conference
Date: Nove...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
IPH
LISTED
EURONEXT
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2025.
“This quarter highlights strong execution across our key programs,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “With FDA clearance...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
10.11.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed.
The planned...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
05.11.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025.
Participants during the call will be:
Jonathan Dickins...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
IPH
LISTED
EURONEXT
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an analyst and investor event focused on lacutamab, an asset with path to potential Accelerated Approval based on existing long-term follow-up data of the Phase 2 TELLOMAK study, providing both clinical perspectives...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
IPH
LISTED
EURONEXT
Innate Pharma Reports First Half 2025 Business Update and Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2025. The consolidated financial statements are attached to this press release.
“With key milestones anticipated over the next 12 months, our primary focus will be...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25th edition of the European Midcap Event being held from September 30 to October 1, 2025 in Paris, France.
The European Midcap Event is a key g...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2025.
Participants during the call will be:
Jonathan Di...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
IPH
LISTED
EURONEXT
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025
News Preview
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as wel...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the company’s CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025.
BTIG, a global financial services firm specializing in investment banking,...
Themefolio
Profiler
Peergroup
© BusinessWire
04.07.2025
IPH
LISTED
EURONEXT
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
News Preview
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as wel...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
17.06.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will participate in the upcoming investor conferences, detailed below.
H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference
Dates: June 24, 2025 | Virtual
Wolfe Research Virtual...
Themefolio
Profiler
Peergroup
© BusinessWire
13.06.2025
IPH
LISTED
EURONEXT
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor conferences, detailed below.
Jefferies Global Healthcare Conference
Dates: June 3 – 5 2025 | New York, USA
The executive team will part...
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
IPH
LISTED
EURONEXT
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive...
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
IPH
LISTED
EURONEXT
Outcome of Innate Pharma’s 2025 Annual General Meeting
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted.
A total of 114 votes were cast out of a total of 43,447,237 shares giving right to 43...
Themefolio
Profiler
Peergroup
© BusinessWire
19.05.2025
IPH
LISTED
EURONEXT
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.
“We are looking forwa...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
IPH
LISTED
EURONEXT
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
IPH
LISTED
EURONEXT
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025.
“The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships,” said Jonathan Dickinson, Chief Executive Off...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
IPH
LISTED
EURONEXT
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
News Preview
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
IPH
LISTED
EURONEXT
Innate Pharma announces conference call and webcast for Q1 2025 business update
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2025.
In addition, members of the executive management team will...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
IPH
LISTED
EURONEXT
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 30, 2025. It can be...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
IPH
LISTED
EURONEXT
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
IPH
LISTED
EURONEXT
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
News Preview
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces €15M Investment by Sanofi
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi.
As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 pe...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
IPH
LISTED
EURONEXT
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) with Sanofi:
As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development o...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
IPH
LISTED
EURONEXT
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to one with a CEO/board of directors. This transformation is part of the Comp...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
IPH
LISTED
EURONEXT
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its annual general meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 22, 2025 in its headquarters, 117 avenue de Luminy, 13009 Marseille.
The Notice of Meeting of this AGM was published on April 16, 2025 in the French legal bullet...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
IPH
LISTED
EURONEXT
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Stifel 2025 Virtual Targeted Oncology Forum being held on April 8 – 9, 2025.
The executive team will participate in a fireside chat scheduled on Wednesday,...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
IPH
LISTED
EURONEXT
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release.
“Our strategy is clear: drive innovation through our ANKET® NK-cell engager platform a...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
IPH
LISTED
EURONEXT
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) Annual Meeting 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
IPH
LISTED
EURONEXT
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below:
Life Sciences Van Lanschot Kempen Conference
Event dates: April 1 – 3, 2025 | Amsterdam, Netherlands
About Innate P...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2024.
Participants during the call will be:...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
IPH
LISTED
EURONEXT
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Leerink Partners 2025 Global Healthcare Conference being held on March 10 – 12, 2025 in W Hotel South Beach in Miami, Florida.
The executive team will par...
Themefolio
Profiler
Peergroup
© BusinessWire
17.02.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sé...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4.
IP...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will host an event for institutional investors and analysts dedicated to its Antibody-Drug Conjugate (ADC) strategy, and particularly Nectin-4, the target of its lead antibody-drug candidate program, IPH4502. The event will be held in New York in a...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2025
IPH
LISTED
EURONEXT
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
News Preview
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as wel...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
IPH
LISTED
EURONEXT
Innate Pharma Announces Transformative Strategy to Accelerate Growth
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide.
"Our updated str...
Themefolio
Profiler
Peergroup
© BusinessWire
20.12.2024
IPH
LISTED
EURONEXT
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA.
Jonathan Dickinson, Chief Executive Officer of Innate Pharma, will...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
IPH
LISTED
EURONEXT
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society o...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2024
IPH
LISTED
EURONEXT
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL).
Innate’s ongoing Phase 1/2, o...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
IPH
LISTED
EURONEXT
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET® asset, have been selected for the American Society of hematology (ASH) Annual Me...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
IPH
LISTED
EURONEXT
Innate Pharma Releases Its 2025 Financial Calendar
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2025 financial calendar:
March 27, 2025: Publication of 2024 financial statements
May 13, 2025: Publication of revenue and cash position for 1Q2025
May 22, 2025: Annual General Shareholders Meeting
September 17, 2025:...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
IPH
LISTED
EURONEXT
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate’s proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
IPH
LISTED
EURONEXT
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2024.
"I’m honored to join Innate Pharma at such a pivotal moment in its evolution,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We achi...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
IPH
LISTED
EURONEXT
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will be presented at the SITC Annual Meeting 2024.
“We are thrilled t...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
IPH
LISTED
EURONEXT
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2024.
Participants during the call will be:
Jonathan Dickin...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
IPH
LISTED
EURONEXT
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conferences, detailed below.
Stifel Healthcare Conference
Event dates: November 18 – 19, 2024 | New York, United States
Jefferies London He...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2024
IPH
LISTED
EURONEXT
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its supervisory Board has appointed Jonathan Dickinson as the Company’s new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of t...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
IPH
LISTED
EURONEXT
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will co-host with the Icahn School of Medicine at Mount Sinai a scientific symposium entitled “Next Generation Immunotherapy Discoveries”. The symposium will be held in a hybrid format on Thursday, October 3, 2024, from 10:00 a.m. to 5:30 p.m. EDT at...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
IPH
LISTED
EURONEXT
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502, its novel and differentiated topoisomerase I inhibitor antibody drug conjugate...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2024
IPH
LISTED
EURONEXT
Innate Pharma Reports First Half 2024 Business Update and Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2024. The consolidated financial statements are attached to this press release.
“We are focused on our growth strategy as we advance our pipeline,” said Hervé Braill...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
IPH
LISTED
EURONEXT
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 (NCT05061550) Phase 2 platform study during the 2024 World Conference on Lung Cancer on September 8, 2024.
The NeoCOAST-2 platform study...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2024
IPH
LISTED
EURONEXT
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2024.
Participants during the call will be:
Hervé Braill...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2024
IPH
LISTED
EURONEXT
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Arvind Sood, EVP, President of US Operations, is to participate in the upcoming investor conference, detailed below.
H.C. Wainwright 26th Annual Global Investment Conference
Date: September 10, 2024 | New York, United Stat...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
